Ibrucent (Capsule 140 mg)

Mantle Cell Lymphoma: Ibrucent is indicated for the treatment of patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Ibrucent is indicated for the treatment of patients with chronic lymphocytic leukemia. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with 17p deletion Ibrucent is indicated for the treatment of patients with chronic lymphocytic leukemia. Waldenstrom Macroglobulinemia (WM): Ibrucent is indicated for the treatment of patients with Waldenstrom Macroglobulinemia (WM). Marginal Zone Lymphoma: Ibrucent is indicated for the reatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD 20-based therapy. * রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন'

Add to cart